Global Insomnia Market Research Report Forecast to 2023

Global Insomnia Market Research Report Forecast to 2023

ID: MRFR/Pharma/0102-HCRR | December, 2017 | Region: Global | 85 pages | Half-Cooked Research Reports

Global Insomnia Market Research Report, by types of therapy (Pharmacological therapy and Non Pharmacological therapy), by drug formulation (Capsules, Tablet and others), by type of diseases (poor quality of sleep, sleep maintenance and other) - Forecast till 2023 


Study Objectives Global Insomnia Market Research Report



  • To provide the Detail Overview of parent market.

  • To provide In-depth market segmentation and sub segmentations.

  • To provide insights about factors affecting the market growth

  • To analyze the market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.

  • To provide Competitive landscape and key players in the market.

  • To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- North America, Europe, Asia Pacific and Middle East and Africa.

  • To provide country level analysis of the market with respect to the current market size and future prospective

  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global insomnia market. 


Intended Audience



  • Manufacturing and packaging industries.

  • Insomnia devices and drug manufacturers

  • Insomnia devices and drug suppliers

  • Biotechnology Companies

  • Bio-Pharmaceutical Companies

  • Research and Development (R&D) Companies

  • Government Research Laboratories

  • Medical Research Institutes 


Figure 1- Global Insomnia Market Share, by region

Insomnia Market


Market Scenario:
Insomnia is a common sleep disorder characterized by difficulties in sleep. Insomnia can exist as it’s alone or conjugated with other psychiatric problems. Insomnia is most common is women and the severity may increase in conditions like pregnancy, postpartum, and menopause. The exact cause of insomnia is still a mystery. Many research has shown that biological, behavioural and psychological factors are responsible for initiating of insomnia. Different types of treatment are available in the market- Pharmacological and non-pharmacological treatment. Global Insomnia market is driving due to increase in the number of insomnia patient across the globe, technological advances and many other. While lack of education and awareness is the major restraining factor for the growth of market.


Global insomnia market is expected to grow at a CAGR of 4.5% during forecasted period of 2017-2023. 


Segmentation
Global Insomnia Market has been segmented on the basis of types of therapy which comprises Pharmacological therapy which is further sub segmented into benzodiazepines, non-benzodiazepines, melatonin receptor agonists and other. Non Pharmacological therapy which is sub segmented into Relaxation therapy, Cognitive Behavioral Therapy, Sleep Hygiene Education, Stimulus Control, Paradoxical Intention and Other. By drug formulation they are segmented as Capsules, Tablet and others. On the basis of condition of diseases they are poor quality of sleep, sleep maintenance and other.


Regional Analysis
On regional basis the global insomnia market is segmented into four regions- North America, Europe, Asia Pacific and Middle East and Africa.  Due to introduction of new technology and new treatments North America is has the highest market for insomnia followed by Europe. Increasing stress is the major problem for increasing the insomnia market in North America and Europe. Asia Pacific and Middle East and Africa has the lowest market for insomnia.


Market Assessment


Insomnia Market-


Key Players for Global Insomnia market
Eisai, Co. (Japan), Pfizer, Inc. (US), Merck & Co Inc (US), Sanofi (France), Takeda Pharmaceutical Company (Japan),  Meda Consumer Healthcare Inc (US), Pernix Therapeutics (US), Purdue Pharma L.P. (US), Consumer Healthcare Inc. (Canada), Dainippon Sumitomo (Japan), ECR Pharmaceuticals (US), Flynn Pharma (UK), Johnson & Johnson (US),  Astellas (UK), Biocodex S A (France), Neurim (Switzerland), SkyePharma (UK), and Vanda Pharmaceuticals Inc. (US).


The report for Global Insomnia Market Research Report of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.

TABLE OF CONTENTS

1    INTRODUCTION    

      1.1    DEFINITION    

      1.2    SCOPE OF STUDY    

            1.2.1    RESEARCH OBJECTIVE    

            1.2.2    ASSUMPTIONS & LIMITATIONS    

                1.2.2.1    ASSUMPTIONS    

                1.2.2.2    LIMITATIONS    

      1.3    MARKET STRUCTURE:    

2    RESEARCH METHODOLOGY    

      2.1    RESEARCH PROCESS:    

      2.2    PRIMARY RESEARCH    

      2.3    SECONDARY RESEARCH:    

3    MARKET DYNAMICS    

      3.1    DRIVERS    

      3.2    RESTRAINTS        

      3.3    OPPORTUNITIES    

      3.4    MACROECONOMIC INDICATORS    

4    MARKET FACTOR ANALYSIS    

      4.1    PORTERS FIVE FORCES MODEL    

      4.2    BARGAINING POWER OF SUPPLIERS    

      4.3    BARGAINING POWER OF BUYERS    

      4.4    THREAT OF NEW ENTRANTS    

      4.5    THREAT OF SUBSTITUTES    

      4.6    INTENSITY OF RIVALRY    

5.    GLOBAL INSOMNIA MARKET, BY TYPES OF THERAPY 

      5.1    PHARMACOLOGICAL THERAPY 

            5.1.1    BENZODIAZEPINES

            5.1.2    NON-BENZODIAZEPINES

            5.1.3    MELATONIN RECEPTOR AGONISTS 

            5.1.4    OTHER

      5.2    NON PHARMACOLOGICAL THERAPY 

            5.2.1    RELAXATION THERAPY

            5.2.2    COGNITIVE BEHAVIORAL THERAPY

            5.2.3    SLEEP HYGIENE EDUCATION

            5.2.4    STIMULUS CONTRO

            5.2.5    PARADOXICAL INTENTION 

            5.2.6    OTHER

6.    GLOBAL INSOMNIA MARKET, BY DRUG FORMULATION 

      6.1    CAPSULES

      6.2    TABLET 

      6.3    OTHERS.

7.     GLOBAL INSOMNIA MARKET, BY DISEASES CONDITION

      7.1    POOR QUALITY OF SLEEP

      7.2    SLEEP MAINTENANCE 

      7.3    OTHER.

8.     GLOBAL INSOMNIA MARKET, BY REGION

      8.1        INTRODUCTION

      8.2        NORTH AMERICA

            8.2.1        US

            8.2.2        CANADA

      8.3        EUROPE

            8.3.1        WESTERN EUROPE

                8.3.1.1        GERMANY

                8.3.1.2        FRANCE

                8.3.1.3        ITALY

                8.3.1.3        SPAIN

                8.3.1.5        UK

                8.3.1.6        REST OF WESTERN EUROPE

            8.3.2        EASTERN EUROPE

      8.4        ASIA

            8.4.1        JAPAN

            8.4.2        CHINA

            8.4.3        INDIA

            8.4.4        AUSTRALIA

            8.4.5        REPUBLIC OF KOREA

      8.5        REST OF ASIA-PACIFIC

      8.6        MIDDLE EAST & AFRICA

9.    COMPETITIVE LANDSCAPE    

      9.1    MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS    

            8.1.1    STRATEGIC PARTNERSHIP    

            9.1.2    MERGER & ACQUISITION    

10    COMPANY PROFILE    

      10.1    EISAI, CO.

            10.1.1    OVERVIEW    

            10.1.2    PRODUCT OVERVIEW    

            10.1.3    FINANCIALS    

            10.1.4    KEY DEVELOPMENTS    

      10.2    MERCK & CO INC

            10.2.1    OVERVIEW    

            10.2.2    PRODUCT OVERVIEW    

            10.2.3    FINANCIALS    

            10.2.4    KEY DEVELOPMENTS    

      10.3    SANOFI

            10.3.1    OVERVIEW

            10.3.2    PRODUCT OVERVIEW    

            10.3.3    FINANCIALS

            10.3.4    STRATEGY    

            10.3.5    KEY DEVELOPMENT    

      10.4    TAKEDA PHARMACEUTICAL COMPANY

            10.4.1    OVERVIEW

            10.4.2    PRODUCT OVERVIEW

            10.4.3    FINANCIALS

            10.4.4    KEY DEVELOPMENTS    

      10.5    PFIZER, INC.

            10.5.1    OVERVIEW

            10.5.2    PRODUCT OVERVIEW    

            10.5.3    FINANCIALS    

            10.5.4    KEY DEVELOPMENTS    

      10.6    OTHERS